USNA Stock Forecast & Price Target

Usana Health Sciences Inc. has projected a slight improvement in organic sales for 2025, with an upward revision of its growth forecast from -6% to -5%, reflecting positive momentum in regions such as Greater China and the Americas. The company benefited from a lower-than-expected tax rate, which contributed an additional $0.1 to earnings per share, while ongoing reductions in material costs and favorable market mix dynamics enhanced year-over-year financial performance. Furthermore, the growth expectations for Usana's Hiya direct-to-consumer segment have increased significantly, with management anticipating a 41%-55% growth rate, indicating strong prospects for future revenue expansion.

Usana Health Sciences, Inc. reported a 6.2% decline in third-quarter sales to $200 million, falling short of the consensus expectation of $206 million, indicating a challenging market environment. Despite an earnings per share (EPS) beat of $0.56 owing to lower SG&A expenses, the company has reduced its EPS guidance for 2024 to $2.45, highlighting a cautious outlook amid ongoing macroeconomic pressures that are suppressing consumer spending. The anticipated flattening of sales growth has been pushed out to 2026, and potential risks related to economic downturns raise concerns about the company's future profitability and cash flow.